A new report released at the BIO International Convention shows that the US bioscience industry has had a $2-trillion economic impact and has accelerated venture capital investment and job growth.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
A report published on Tuesday highlights the frightening extent of sexual harassment in STEM, showing that it remains prevalent and largely unchanged.
The deal gives Editas Medicine an exclusive ‘first’ to negotiate for licenses to genome-editing inventions that rise from the sponsored research.
Non-profit Bill & Melinda Gates Medical Research Institute (MRI) has officially been launched, creating a new vision for drug development with a clear focus on the millions of people that die annually from contracting malaria, tuberculosis and diarrheal diseases.
Probably not. But there is an increasing demand for people with data and computing skills, and the life sciences sector in California may be losing the battle with Silicon Valley for those people.
Microbiotica has entered into a multi-year strategic collaboration with Genentech, a Roche company, to discover, develop, and commercialise biomarkers, targets, and medicines for inflammatory bowel disease.
Sometimes a new company catches the eye, and this week that company is nference, a Cambridge MA-based start-up developing AI technology to discover and develop drugs more effectively. AI is no longer new in this space, so why does nference grab our attention?
Yesterday’s news about the Oncotype DX test that could enable a lot of patients with breast cancer to safely forgo chemotherapy, is massive news for the breast cancer field. But it’s also big news for Genomic Health, the developer of the test.
People’s medical and health history might become more than just a blueprint for doctor’s actions, now that blockchain start-up Nebula Genomics, and Hong Kong-based Longenesis are partnering up.